Abstract:Background: Individuals with a loss-of-function single-nucleotide polymorphism in the gene encoding PTPN22 have an increased risk for autoimmune diseases, and patients with cancer with such alleles may respond better to checkpoint blockade immunotherapy. Studies in PTPN22 knockout (KO) mice have established it as a negative regulator of T cell responses in cancer models. However, the role of PTPN22 in distinct immune cell compartments, such as dendritic cells (DCs), remains undefined. Methods: We developed a novel PTPN22 conditional KO (cKO) mouse model that enables specific deletion in CD11c+ DCs by crossing to CD11c-Cre transgenic mice. Antitumor immunity was characterized using the B16.SIY and MC38.SIY cancer models and immune profiles of relevant tissues were evaluated by spectral flow cytometry. Antigen uptake, processing, and presentation, as well as DC proliferation to Flt3L, were characterized ex vivo. Results: Deletion of PTPN22 in DCs resulted in augmented antitumor immunity in multiple syngeneic tumor models. Tumor antigen-specific CD8+ T cells were increased in the tumor microenvironment (TME) of PTPN22 cKO mice and improved tumor control was CD8+ T cell-dependent. Augmented T cell priming was also detected at early time points in the draining lymph nodes, and these effects were correlated with an increased number of proliferating CD103+ DCs, also seen in the TME. In vitro studies revealed increased DC proliferation in response to Flt3L, as well as increased antigen processing and presentation. PTPN22 cKO mice bearing MC38 parental tumors showed combinatorial benefit with anti-PD-L1 therapy. Conclusions: Deletion of PTPN22 in DCs is sufficient to drive an augmented tumor antigen-specific T cell response, resulting in enhanced tumor control. PTPN22 negatively regulates DC proliferation and antigen processing and presentation. Our work argues that PTPN22 is an attractive therapeutic target for cancer immunotherapy and highlights the potential to modulate antitumor immunity through the manipulation of DC signaling.

Tumor Suppressor Adenomatous Polyposis Coli Sustains Dendritic Cell Tolerance Through IL-10 in a B-Catenin-dependent Manner

β-Catenin in Dendritic Cells Negatively Regulates CD8 T Cell Immune Responses through the Immune Checkpoint Molecule Tim-3

Nuclear adenomatous polyposis coli suppresses colitis-associated tumorigenesis in mice

Abstract 5036: Tumor-induced Activation of the Wnt/β-catenin/TCF4 Pathway in Dendritic Cells Promotes Immune Tolerance

Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/β-Catenin Signaling in Human Melanoma Cells

Data from Autocrine Complement Inhibits IL10-Dependent T-cell–Mediated Antitumor Immunity to Promote Tumor Progression

Chromatin-associated APC Regulates Gene Expression in Collaboration with Canonical WNT Signaling and AP-1.

The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes

Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells.

Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis

Dendritic cells transduced with T-bet and IL-12 effectively restrict immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in a murine tumor model (46.26)

Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy

Enhanced Apc Min/ Plus Adenoma Formation after Epithelial CUL4B Deletion by Recruitment of Myeloid-Derived Suppressor Cells

Il-10 Enhances Ctl-Mediated Tumor Rejection By Inhibiting Highly Suppressive Cd4(+) T Cells And Promoting Ctl Persistence In A Murine Model Of Plasmacytoma

Β-Catenin Promotes Regulatory T-cell Responses in Tumors by Inducing Vitamin A Metabolism in Dendritic Cells.

Enhanced gut barrier integrity sensitizes colon cancer to immune therapy

Apc Regulates The Function Of Hematopoietic Stem Cells Largely Through Beta-Catenin-Dependent Mechanisms

Interleukin-10 Reorganizes The Cytoskeleton Of Mature Dendritic Cells Leading To Their Impaired Biophysical Properties And Motilities

T cell intrinsic deletion of the adenomatous polyposis coli gene causes homeostatic proliferation and inflammatory bowel disease (BA11P.142)

Cd11b Deficiency Suppresses Intestinal Tumor Growth by Reducing Myeloid Cell Recruitment

Differentially Tolerized Mouse Antigen Presenting Cells Share a Common miRNA Signature Including Enhanced mmu-miR-223-3p Expression Which Is Sufficient to Imprint a Protolerogenic State